Southern Marine Science and Engineering Guangdong Laboratory and Guangdong Medical University have disclosed peptides acting as angiotensin-converting enzyme (ACE) inhibitors reported to be useful for the treatment of hypertension.
Data on the development of novel noncationic macrocyclic peptides for inhibiting GTPase KRAS signaling for the potential treatment of cancer were presented by investigators from Merck & Co. Inc.
Ideaya Biosciences Inc. reported the achievement of the first preclinical development milestone under its ongoing collaboration with GSK plc for a polymerase (Pol) theta-helicase development candidate.
The FDA has cleared Inhibikase Therapeutics Inc.'s IND application for IkT-001Pro for the treatment of chronic myelogenous leukemia (CML). IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson (Abl) kinase inhibitor, Gleevec (imatinib).
Anakuria Therapeutics Inc. has identified rapamycin derivatives acting as mTOR complex 1 (mTORC1) inhibitors reported to be useful for the treatment of diabetic nephropathy, chronic obstructive pulmonary disease, epilepsy, fragile X syndrome, urinary tract infection, heart failure, glaucoma and autosomal dominant polycystic kidney, among others.
Scientists have discovered a new antibiotic called evybactin that is able to selectively target Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB) lung infections. As described in NatureChemicalBiology on Aug. 22, 2022. the work is still at an early stage and requires further validation. But, if successful in clinical trials, evybactin could form part of a new group of specific antibiotics designed to target TB.
he continuing emergence of immune-evasive variants of SARS-CoV-2 virus represents a major challenge in controlling COVID-19 pandemic disease. Researchers from Stanford University have tested the immunogenicity and protective effect of the receptor binding domain (RBD)-I53-50 AS03-adjuvanted nanoparticle vaccine in nonhuman primates.
The FDA has cleared Century Therapeutics' IND application to commence a phase I study of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies.
In the search for novel antibacterial agents, some targets have been engaged to kill Gram-positive but not Gram-negative organisms, due to lack of accumulation of proposed agents.
Regulatory T cells (Tregs) are contributors of tumor immune evasion; Ikaros family zinc finger protein 2 (IKZF2) plays a crucial role in the maintenance of function and stability of Tregs. IKZF2-deificent tumoral Tregs produce inflammatory cytokines and enhance antitumoral immunity in mice.
RSS
